Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA7 | P43166 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.55 |
| ▸ | CA4 | P22748 | 2/20 | 0.55 |
| ▸ | CA6 | P23280 | 2/20 | 0.55 |
| ▸ | TPMT | P51580 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2892480 | 0.89 | MAPT (0.64) | MAPTALDH1A1CA1CA2CA12 | |
| SCHEMBL966378 | 0.87 | CA12 (0.71) | ALDH1A1CA1CA2CA12CA7 | |
| SCHEMBL30221732 | 0.86 | CA12 (0.65) | MAPTALDH1A1CA1CA2CA12 | |
| SCHEMBL7019824 | 0.86 | CA12 (0.65) | MAPTALDH1A1CA1CA2CA12 | |
| SCHEMBL310059 | 0.86 | MAPT (0.60) | MAPTALDH1A1CA1CA2CA12 | |
| SCHEMBL2406876 | 0.86 | MAPT (0.60) | MAPTALDH1A1CA1CA2CA12 | |
| Hydrochloric Acid SCHEMBL17667160 | 0.85 | CA12 (0.69) | ALDH1A1CA1CA2CA12CA7 | |
| SCHEMBL7284622 | 0.84 | ALDH1A1 (0.61) | ALDH1A1CA1CA2CA12CA7 | |
| SCHEMBL17560206 | 0.83 | TSHR (0.56) | MAPTALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL7401464 | 0.83 | ALDH1A1 (0.53) | MAPTALDH1A1CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509470-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12258316-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-03-25 | — | — | US | disclosed |
| US-12006326-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-11572367-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-11572367-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-11505558-B1 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220356189-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2022-11-10 | — | — | US | disclosed |
| WO-2006138218-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060281740-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-12-14 | — | — | US | disclosed |
| EP-1723114-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| US-20050234120-A1 | Aryl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | disclosed |
| US-20050209302-A1 | Alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-22 | — | — | US | disclosed |
| WO-2005087738-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050203133-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
| US-20050203104-A1 | Cycloalkyl - containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | disclosed |
| CN-1668589-A | Indoline derivatives substituted in the 6-position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-09-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234120-A1 | Aryl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | GSK3B, GSK3A, CSNK2A3 | MAPT 181/4885ALDH1A1 1889/4885CA1 4327/4885 |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | MAPT 545/4885ALDH1A1 2036/4885CA1 4545/4885 |
| US-12509470-B2 | Antiviral heterocyclic compounds | NR3C1, ZC3HAV1, HAVCR2 | MAPT 4847/4885ALDH1A1 3560/4885CA1 2525/4885 |
| US-20050203133-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | MAPT 4020/4885ALDH1A1 1082/4885CA1 4223/4885 |
| US-20050203104-A1 | Cycloalkyl - containing 5-acylindolinones, the preparation thereof and their use as medicaments | GSK3B, GSK3A, CSNK1G3 | MAPT 247/4885ALDH1A1 3162/4885CA1 3361/4885 |
| US-11505558-B1 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | MAPT 4608/4885ALDH1A1 2176/4885CA1 3861/4885 |
| US-12258316-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | MAPT 4020/4885ALDH1A1 1082/4885CA1 4223/4885 |
| US-20220356189-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | MAPT 4608/4885ALDH1A1 2176/4885CA1 3861/4885 |
| US-12006326-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | MAPT 4608/4885ALDH1A1 2176/4885CA1 3861/4885 |
| US-11572367-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | MAPT 4608/4885ALDH1A1 2176/4885CA1 3861/4885 |
| US-20060281740-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM3, CHRM5 | MAPT 3983/4885ALDH1A1 1522/4885CA1 3720/4885 |
| US-20050209302-A1 | Alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | GSK3A, GSK3B, PYGL | MAPT 249/4885ALDH1A1 2722/4885CA1 3742/4885 |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | MAPT 4608/4885ALDH1A1 2176/4885CA1 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.